Parkinson's disease

BMJ

Volumn 318, Issue 7179, 1999, Pages 311-314

  Schapira, A H V ^a  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIPARKINSON AGENT; LEVODOPA; NEUROPROTECTIVE AGENT; SELEGILINE;

CELL DEATH; DISEASE CONTROL; DOPAMINERGIC SYSTEM; ENVIRONMENTAL FACTOR; HEREDITY; HUMAN; NERVE CELL; ONSET AGE; PARKINSON DISEASE; PATHOGENESIS; PRIORITY JOURNAL; SHORT SURVEY; SYMPTOM;

ANTIPARKINSON AGENTS; CELL DEATH; HUMANS; NEURONS; PARKINSON DISEASE; PROGNOSIS;

EID: 0033616458     PISSN: 09598138     EISSN: 14685833     Source Type: Journal    
DOI: 10.1136/bmj.318.7179.311     Document Type: Article

References (17)

1. Golbe LI. Genetics of Parkinson's disease. In: EllenbergJH,KollerWC,LangstonKW, eds. Etiology of Parkinson's disease. New York: Marcel Dekker, 1995: 115–140.
2. Polymeropoulos M, Lavedan C, Leroy E, Ide SE, Dehejia A, Dutra A, et al. Mutation in the α-synuclein gene identified in families with Parkinson's disease. Science 1997; 276: 2045–2047.
3. Krüger R, Kuhn W, Muller T, Woitalla D, Graeber M, Kosel S, et al. Ala30Pro mutation in the α-synuclein in Parkinson's disease. Nature Genet 1998; 18: 106–108.
4. Kitada T, Asakawa S, Hattori N, Matsumine H, Yamamura Y, Monoshima S, et al. Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature 1998; 392: 605–608.
5. Gasser T, Müller-Myhsok B, Wszolek Z, Oehlmann R, Calne DB, Bonifati V, et al. A susceptibility locus for Parkinson's disease maps to chromosome 2p13. Nature Genet 1998; 18: 262–265.
6. Schapira AHV, Gu M, Taanman J-W, Tabrizi SJ, Seaton T, Cleeter M, et al. Mitochondria in the aetiology and pathogenesis of Parkinson's disease. Ann Neurol 1998; 44(suppl 1): S89–S98.
7. Gu M, Cooper JM, Taanman J-W, Schapira AHV. Mitochondrial DNA transmission of the mitochondrial defect in Parkinson's disease. Ann Neurol 1998; 44: 177–186.
8. Hirsch EC, Hunot S, Damier P, Faucheuz. Glial cells and inflammation in Parkinson's disease: a role in neurodegeneration? Ann Neurol 1998; 44(suppl 1): S115–S120.
9. Zamzami N, Hirsch T, Dallaporta B, Petit PX, Kroemer G. Mitochondrial implication in accidental and programmed cell death: apoptosis and necrosis. J Bioenerg Biomembr 1997; 29: 185–193.
10. Tatton NA, Maclean-Fraser A, Tatton WG, Perl DP, Olanow CW. The fluorescent double-labelling method to detect and confirm apoptotic nuclei in Parkinson's disease. Ann Neurol 1998; 44(suppl 1): S142–S148.
11. Limousin P, Krack P, Pollack P, Benazzouz A, Ardouin C, Hoffmann D, et al. Electrical stimulation of the subthalamic nucleus in advanced Parkinson's disease. N Engl J Med 1998; 339: 1105–1111.
12. Olanow CW, Kordower JH, Freeman TB. Fetal nigral transplantation as a therapy for Parkinson's disease. Trends Neurosci 1996; 19: 102–109.
13. Fahn S. Welcome news about levodopa, but uncertainty remains. Ann Neurol 1998; 43: 551–554.
14. Murer MG, Dziewczapolski G, Menalled LB, Garcia MC, Agid Y, Gershanik O, et al. Chronic levodopa is not toxic for remaining dopamine neurons, but instead promotes their recovery in rats with moderate nigrostrial lesions. Ann Neurol 1998; 43: 561–575.
15. Seaton TA, Cooper JM, Schapira AHV. Free radical scavengers protect dopaminergic cell lines from apoptosis induced by mitochondrial complex I inhibitors. Brain Res 1997; 777: 110–118.
16. Mytilineou C, Radcliffe PM, Olanow CW. L-(-)-desmethylselegiline, a metabolite of selegiline [L-(-)-deprenyl], protects mesencephaliic dopamine neurons from excitotoxicity in vitro. J Neurochem 1997; 68: 434–436.
17. Parkinson Study Group. Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease. N Engl J Med 1993; 328: 176–183.